Tempus AI (TEM) climbed 6.9% to $66.21 on Thursday after BTIG Research raised its price target on the stock from $70 to $80 while keeping its Buy rating intact. Trading volume was heavy, with more than 4.5 million shares changing hands by midday. The stock had closed the prior session at $61.25, making Thursday's advance one of TEM's stronger single-day gains in recent weeks.

The rally was driven by two overlapping catalysts: a fresh endorsement from BTIG and a major cancer trial milestone involving Merck and Moderna's mRNA therapy — a program that runs on Personalis' sequencing platform, the genomics company Tempus AI agreed last month to acquire for $1.5 billion. The combination of the raised price target, the landmark trial readout tied to its pending acquisition, and a recent earnings beat has kept the stock in focus for investors. Tempus, which went public on Nasdaq in June 2024, sells AI-enabled genomic sequencing and clinical-data services to physicians and drug developers, and both of Thursday's catalysts touched that core business directly.

Trial Milestone Ties Into Personalis Deal

On Wednesday, Merck and Moderna released Phase 3 results for a customized mRNA cancer therapy called intismeran autogene, which is used in combination with Keytruda, Merck's top-selling immunotherapy. The trial, known as INTerpath-001, showed that the combination improved recurrence-free survival in patients with resected melanoma — melanoma that has been surgically removed but carries a risk of returning. It was the first successful Phase 3 readout for a personalized mRNA-based cancer treatment, and the companies are also running a second Phase 3 trial, INTerpath-002, evaluating the same combination in non-small cell lung cancer.

Moderna uses Personalis' sequencing platform to analyze tumor tissue and identify the specific neoantigens — the patient-specific tumor mutations an individualized therapy is designed to train the immune system against — needed to make each individualized dose. That connection brought Tempus AI directly into the conversation, as investors linked the trial's success to the company Tempus AI is in the process of acquiring. Tempus AI had previously partnered with Personalis to commercialize minimal residual disease tests, which detect trace amounts of cancer DNA that can remain in the blood after surgery, and last month it announced a deal to buy Personalis outright for $1.5 billion — connecting the trial results directly to TEM. The acquisition remains subject to customary closing conditions before it can be completed.

Q2 Earnings Beat Expectations

Tempus AI posted its most recent quarterly results on July 30, and the numbers came in ahead of Wall Street's expectations. The company reported an adjusted loss of $0.04 per share, beating the consensus estimate of -$0.14 by $0.10. Revenue came in at $382.49 million, above the $379.69 million analysts expected, representing 21.6% growth year over year. Tempus generates that revenue across two core segments — genomics, built on its sequencing-based testing business, and data, which licenses de-identified clinical and molecular data to pharmaceutical companies.

A year ago, the company posted a loss of $0.22 per share for the same period. Tempus AI still carries a negative net margin of 17.77% and a negative return on equity of 50.28%. Analysts as a group expect the company to post a full-year loss of $1.38 per share.

Analyst Picture Remains Mixed

Beyond BTIG, the broader analyst community is divided on TEM. Piper Sandler cut its price target from $58 to $56 on August 4, assigning a neutral rating. Guggenheim raised its target to $65 with a Buy rating in July. Wolfe Research started coverage in June with a peer perform rating, and Weiss Ratings moved the stock from sell (e+) to sell (d-) in August.

Across all firms, nine analysts rate TEM a Buy, six rate it a Hold, and two rate it a Sell. The overall consensus rating is Hold, with an average price target of $65.69 — slightly below where the stock finished after Thursday's move.

Insider Selling and Trading Levels

Insider selling has been active in recent months. CFO James Rogers sold $634,095 worth of stock in June, and CEO Ryan Fukushima sold $1.91 million worth in July. Over the past 90 days, insiders have sold a combined $33.26 million in stock.

At $66.21, TEM is trading above both its 50-day moving average of $52.10 and its 200-day moving average of $51.16.